Ivf market trends and an overview

FLOW OF THE PRESENTATION

Assisted reproductive technologies (ART)
Success rate of ART Methods
IVF - InVitro Fertilization An Overview
IVF Treatment Plan
IVF Cost Aspects
Fertility treatments Cost Aspects
Fertility treatments Cost COMPARISON ACROSS GLOBE
Drugs usually prescribed in IVF Treatment
Top 10 Players in Indian IVF Segment Market & Emerging Players in IVF Market
INDIA IVF Market Overview ,Market Trends & Potential
Regulatory Aspects for IVF in India
THE ASSISTED REPRODUCTIVE TECHNOLOGIES (REGULATION) BILL – 2010
Regulatory Aspects for IVF across globe and comparison
The factors affecting IVF Market in India and across globe
Recommendations & Suggestions

ASSISTED REPRODUCTIVE TECHNOLOGIES (ART)

Commonly used method in %
Assisted reproductive technologies
(ART) refer to infertility treatments
that involve the handling of eggs or
embryos.
This includes IVF, GIFT, and ZIFT.
ZIFT (Zygote Intra

3
With GIFT (gamete intrafallopian Fallopian Transfer)

transfer), the egg and sperm, or
gametes, are not fertilized outside
the body. Instead, they are placed GIFT (Gamete Intra Commonly used

2
Fallopian Transfer) method in %
together into one of the woman's
fallopian tubes
ZIFT: With ZIFT (zygote intrafallopian IVF ( In Vitro

1
Fertilization )
transfer), the zygote is placed in
one of the fallopian tubes. This is
usually done via laparoscopic 0 20 40 60 80

surgery.

SUCCESS RATE OF ART METHODS

Live birth rate of each IVF Cycle
For women under age 35, the live birth rate Rate in %
for each IVF cycle is 30% to 35%.
For women ages 35 to 37, the rate is 25%.
35
For women ages 38 to 40, the rate is 15% to
20%,
30
For women over age 40, the success rate is
6% to 10%.
25
ART is also sometimes performed with
donor eggs and/or sperm.
For women whose eggs are of lower 20
quality, donor eggs may be the best
option. Live birth rate of
15 each IVF Cycle Rate
The live birth rate for egg donation is in %
between 40% to 45%, but less than
10% of couples choose to use donor 10
eggs or sperm.
5

0
<35 35-37 38-40 > 40

1 2 3 4

IVF - INVITRO FERTILIZATION AN OVERVIEW
What Is IVF?
IVF stands for in vitro fertilization, which
literally means "in lab conception." With
IVF treatment, the egg is fertilized with
sperm in a petri dish. Typically, many eggs
are retrieved from the biological mother
(who may or may not be the intended
parent), as not every egg will fertilize, and
not every fertilized egg will become a
viable embryo.

Indications:
 Bilateral blocked Fallopian tubes
Severe endometriosis
Pelvic inflammatory disease with severe
adhesion
Premature Menopause
Failed reversal of Vasectomy/ Tubectomy
Obstructive azoospermia
Genetic diseases
Menopause
Surrogacy (Traditional/ Gestational)

CRYOPRESERVATION

A few days after fertilization, the best embryo or embryos are transferred to the
mother or surrogate's uterus via a catheter through the cervix. Any extra
embryos may be cryopreserved for future cycles.

IVF TREATMENT PLAN
IVF- Treatment Plan

• Day 1 . Inj Lupride, 0.2 ml sc. ( Downregulation starts)
Day 2 . Inj Lupride, 0.2 ml sc.
Day 3 . Inj Lupride, 0.2 ml sc.
• Vaginal ultrasound scan to confirm there is no ovarian cyst. If there is no cyst, we can commence superovulation.
• If there is a cyst, we aspirate/ puncture it under ultrasound guidance and continue with the treatment.
Day 4 Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IM. Superovulation starts.
Day 5 Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IM
Day 10 . Inj Lupride, 0.2 ml sc. Inj Menogon ( 75 IU), 4 amp IM.
Vaginal ultrasound scan to monitor follicular growth
The Lupride and Menogon injections will continue on a daily basis;
and scans will be performed every alternate day, until the follicles are mature.
This is usually Day 14- Day 16 for most patients. At this time, an HCG injection will be given, and eggs retrieved 36 hours after this.
Embryo transfer is performed 3 days later; and supernumerary embryos, if any, are cryopreserved.
After the transfer, luteal phase support is provided with daily Progynova ( estradiol valerate2 mg, 3 tab daily; and Uterogestan ( 200 mg), 6 vaginal
suppositories daily.
You can travel back 3 days after the embryo transfer.
14 days after the transfer, you need to do a blood test for beta HCG to confirm a pregnancy

IVF COST
What Does IVF Cost?
The average cost for IVF is $12,000, but this can vary depending,
on what technologies are being used. IVF with egg donation is the most costly, with
one cycle being anywhere from $25,000 to $30,000.

FERTILITY TREATMENTS COST ASPECTS

Sr. No. Activities for Infertility Treatment INR USD $
1 Consultation 5000-10000 20
2 Semen Analysis 200 - 500 10
3 Hysterosalpingogram 500 - 2000 40
4 Hormonal blood assays (FSH, LH, prolactin, estrogen, progesterone) 200-400 10
5 Testicular biopsy 2000 - 10000 200
6 Endometrial biopsy 500 - 2000 400
7 Diagnostic Laparoscopy 10000 -40000 1000
8 Operative Laparoscopy 25000 - 50000 1200
9 Major surgery (microsurgery for tubal repair) 40000 - 65000 1000
10 IUI (insemination) 3000 - 15000 500
11 TID (Therapeutic insemination by donor), per cycle 8000 - 20000 400
12 HMG treatment cycle (for superovulation) 8000 - 20000 400
13 GIFT IN VITRO 50000 - 120000 3500
FERTILIZATION COST
14 IVF 50000 - 120000 3000
15 Embryo freezing 40000 - 80000 3500
16 Microinjection (ICSI) 80000 - 150000 3500
17 Preimplantation genetic diagnosis 150000 - 200000 5000

COST COMPARISON ACROSS GLOBE
Cost Comparison
NDIA IS MOST
The Comparative Costs between India and other developed countries like US, UK, and FAVOURITE AND
Singapore -
SELECTED
Approximate Figures In US Dollars.

UK SINGAPO
US INDIA
(Private) RE
upto upto upto
1 Bone Marrow Transplant -
200,000 200,000
25,000
2 Bypass Surgery 35,000 25,000 - 6,000
3 Breast Lump Removal - 3,200 1,000 700
4 Haemorrhoidectomy - 3,800 1,500 1000
5 Knee Joint Replacement - 15,000 7,000 5,000
6 Lasik Surgery 4,000 2,800 1,600 700
7 No Stitch Cataract Surgery 4,500 2,600 - 700
8 In-vitro fertilisation (IVF) cycle 15,000 - - 1,800
9 Hernia Correction 2,800 2,700 2,500 1,000
10 Dental Implants 3500 2800 1600 800

* These rates are indicative of approximate costs. The actual rates will vary on case to case basis.

DRUGS USUALLY PRESCRIBED IN IVF TREATMENT
Sr. No. Generic Name Brand Name
1 Follitropin Alfa
Gonal - F
(Recombinant FSH)
2 Follitropin Beta
Follistim / Puregon
( Recombinant FSH)
3 FSH/Urofollitropin Fostimon / Fertinex/ Bravelle
4 HMG Repronex / Menopur / Merional
5 HCG Pregnyl / Profasi / Novarel
6 Lueproreline/Leuprolide
Lupron / Enantone / Procrin
(GnRH agonist)
7 Naferelin Acetate Spray
Synarel
(GnRH agonist)
8 Ganirelix
Antagon / Orgalutran
(GnRH agonist)
9 Cetrorelix
Cetrotide
(GnRH agonist)
10 Progesterone Suppositories Prometrium / Cyclogest
11 Progesterone Capsules Prometrium / Utrogestan
12 Progesterone 8% Gel Crinone
13 Progesterone injections Gestone
14 Clomiphene Clomid / Serophene
15 Letrozole Letroz/ Femara
16 Methylprednisolone
Medrol / Medrone
(steroid)
17 Doxycycline Caps
Doxycycline
(antibiotic)
18 Estradiol Vvelle / Estraderm / Estradot
19 Estradiol Valerate Progynova/ Estrace / Climaval
20 Desogestrel
Desogen / Marvellon
(Low dose Birth control pill)

INDIA IVF MARKET OVERVIEW

India has a large population of 1.22 Billion people
and infertility in the country is rising at a rapid rate
(about 30 Million couples suffer from infertility).

Infertility or the inability to have children refers to a range of
disorders some of which affect the male, and some the
female, and contribute to childlessness in a couple.

There is also something called unexplained infertility, where
doctors are unable to provide a medical explanation for the
couple’s inability to conceive.

INDIA IVF MARKET POTENTIAL

In India, approximately 15% - 20% of married couple's in their fertile age group,
suffer from infertility and it is on the increase because of urbanization, pollution, chemical
exposure, stress, competitive work environment, fast-paced lifestyles, late settlement in life,
more women opting to work, increased incidence of diabetes, pelvic inflammatory
diseases, etc.

Today, arrays of treatment options to treat infertility are readily available in India.
These include medications for ovulation induction; endoscopic surgery to correct anatomical
problems; and the assisted reproductive technologies, including IUI, IVF, and ICSI (intra
cytoplasmic sperm injection).

India has become one of the favored destinations for infertility treatments such as IVF due to
several factors including its medical expertise, state-of-the-art technology (which is at par with
the best in the world), and a cost-effective health care system.

MARKET SHARE THERAPEUTIC CATEGORY WISE INDIA IVF MARKET

Market Share in %
1 Gonadotropins FSH LH
2 HMG ( Human Menopausal Gonadotropins, Menotropins)
3 HCG
Sr. No. Therapeutic Category Market Share in %
4 Synthetic GnRH (Gonadotropins Releasing Hormones)
5 GnRH Analogues
1 Gonadotropins FSH LH 10
6 GnRH antagonists 2 HMG ( Human Menopausal Gonadotropins, Menotropins) 15
7 Growth Hormones 3 HCG 9
8 Steroids
4 Synthetic GnRH (Gonadotropins Releasing Hormones) 16
9 Antibiotics
10 Estrogen Antagonists ( Aromatase inhibitors) 5 GnRH Analogues 7
6 GnRH antagonists 5
7 Growth Hormones 12
12% 10% 8 Steroids 6
8% 15%
6%
9 Antibiotics 8
9% 10 Estrogen Antagonists ( Aromatase inhibitors) 12
12%

5% 16%
7%

TOP 10 PLAYERS IN INDIAN IVF SEGMENT MARKET
 Sun Pharmaceutical Industries Ltd
 Lupin Pharma
 Zydus-Cadila Healthcare Ltd
 Intas Pharmaceuticals Ltd
 CIPLA
 Emecure House
 Bharat Serums and Vaccines Ltd
 Uni-Sankyo Limited
 Serum Institute of India
 Alembic Limited

Other Emerging Players are:
 Lifemedicare
 Svizera Laboratories Private Limited
 VHB Life Sciences Inc
 Plethico Pharmaceuticals Limited
 Ferring BV

SUN PHARMA IVF SEGMENT MARKET LEADER IN INDIA

Famous Brands of SUN Pharmaceutical LTD :
1. leuprolide acetate :
Brand Name : LUPRIDE
Dosage Form : Injectable
Strengths available : 1 mg/ 4 mg/ 11.2 mg/3.75 mg/22.5 mg
2. Gonadotropin chorionic
Brand Name : FERTIGYN
Strengths available : 1000/2000/5000 IU in Ampoules
10000 IU in Vials
3. Follitropin beta
Brand Name : OVITROP-R
Strengths available : 1.20 ml/1.60 ml/0.40 ml
4. Letrozole :
Brand Name : LETOVAL / LETROZ
Dosage Form : Tablets
Strengths available : 2.5 mg

MONOPLOY OF PLAYERS IN SOME THERAPEUTIC CATEGORY IN INDIA IVF MARKET

1. For Cetrorelix acetate Injectable : only 1 Player in India Market
CISCURE by EMECURE
2. For Choriogonadotropin alfa Molecule in India only 2 Players
(OVITRELLE ) Merck KGaA & (PUBERGEN-HP ) UNI SANKYO
3. For Follitropin beta : only 3 Players
( OVITROP-R ) by Sun Pharma
( RECAGON ) by ORGANON
( PUREGON-R ) by ABOTT
4. For Letrozole, leuprolide acetate, urofollitropin, gonadotropin chorionic
more than 25 players are present in Domestic Market

REGULATORY ASPECTS INDIA
MINISTRY OF HEALTH & FAMILY WELFARE , GOVT. OF INDIA, NEW DELHI
INDIAN COUNCIL OF MEDICAL RESEARCH , NEW DELHI
CHAPTER – II 5-11
CONSTITUTION OF AUTHORITIES TO REGULATE ASSISTED
REPRODUCTIVE TECHNOLOGIE
3. Establishment of National Advisory Board 5
4. Meetings of National Advisory Board 5-6
5. Functions of National Advisory Board 6
6. Establishment of State Boards 7
7. Meetings of State Boards 7
8. Powers and functions of State Boards 8
9. Term of office, conditions of service, etc., of Chairperson 8-9
and other members of State Boards
10. Procedure of State Boards 9-10
11 Constitution and functions of the Registration Authority 10
12. Proceedings before State Boards to be judicial proceedings 10-11


CHAPTER – III 12-14

PROCEDURES FOR REGISTRATION AND COMPLAINTS
13. Registration and accreditation of clinics 12

14. Who may apply for registration 13

15. Grant of registration 13

16. Renewal, suspension or revocation of registration 14 CHAPTER – V 20-22
17. Registration Authority to inspect premises 14 SOURCING, STORAGE, HANDLING AND
18. Applicability to ART banks and research organizations 14 RECORD KEEPING FOR
19. Appeal to the State Board 14
GAMETES, EMBRYOS AND SURROGATES
CHAPTER – IV 15-19
26. Sourcing of gametes 20-21
DUTIES OF AN ASSISTED REPRODUCTIVE TECHNOLOGY CLINIC

20. General duties of assisted reproductive technology clinics 15-17 27. Storage and handling of gametes
and embryos 21
21. Duty of the assisted reproductive technology clinic to 17

obtain written consent 28. Records to be maintained by the ART
22. Duty of the assisted reproductive technology clinic to keep 17-18
bank 22
accurate records 29. Restriction on sale of
23. Duties of assisted reproductive technology clinics using 18 gametes, zygotes and embryos 22
gametes and embryos

24. Pre-implantation Genetic Diagnosis 19

25. Sex selection 19


CHAPTER – VIII 30-32
CHAPTER – VI 23-24 OFFENCES AND PENALTIES

REGULATION OF RESEARCH ON EMBRYOS, GAMETES OR 37. Prohibition of advertisement relating to pre-natal determination 30
OTHER
of sex and punishment for contravention
HUMAN REPRODUCTIVE MATERIAL
38. Offences and penalties 30-31
30. Permission of the Department of Health Research for
39. Presumption in the case of conduct of pre-natal diagnostic 31
research 23
techniques
31. Regulation of research 23-24
40. Penalty for contravention of the provisions of the Act or rules 31

for which no specific punishment is provided

41. Offences by companies 31-32

42. Offence to be cognizable 32

CHAPTER – VII 25-29 CHAPTER – IX 33-35

RIGHTS AND DUTIES OF PATIENTS, DONORS, SURROGATES AND MISCELLANEOUS

CHILDREN 43. Maintenance of records 33

32. Rights and duties of patients 25 44. Power to search and seize records etc. 33

33. Rights and duties of donors 25 45. Power to remove difficulties 33

34. Rights and duties in relation to surrogacy 26-28 46. Protection of action taken in good faith 34

35. Determination of status of the child 28-29 47. Power to make regulations 34

36. Right of the child to information about donors or surrogates 48. Power of the Central Government to make rules 34-35
29
49. Power of State Government to make rules 35

50. Act to have effect in addition to other Acts 35

TEAM SELECTION AND FACTOR AFFECTING
• TEAM SELECTION IS MOST IMPORTANT FACTOR FOR MARKETING STRATEGY
FOR ANY PHARMACEUTICAL COMPANY,
• For Product Management Team : its important to update the data about the
clinics For infertility treatment and other diagnostics /blood testing procedures
while Each IVF Cycles ,advances in technology for the same
• Also understanding the IVF Procedure and the medication dosage regimen during
entire process is another critical aspect.
• Understanding Short term long term protocol for IVF Procedures ,
• As on date there are more than 20,000 Infertility clinics in India and Majority are in
Mumbai , at 2nd place Bangalore and at 3rd place Delhi is there in India .
• There are more than 15,000 Doctors /Surgeons are included in this market
• Apart from medical teams , in India some clinics provide total package for foreign
visitors from the day of beginning to end of the treatment .
• Team selection should be based on the factors mentioned in other slide

THE FACTORS AFFECTING TEAM SELECTION FOR IVF MARKET
1. Competitive Landscape in same region/ state
2. Understanding of Unorganized & Fragmented Market
3. Understanding India Total Fertility Rate Profile
4. Updates about merging In Vitro Fertilization (IVF) Market Trends
5. Awareness about India Fertility Tourism
6. Updating Technological Advances in Treatment Procedures
7. Considering Changing Lifestyle Effecting Fertility Profile Among
Youngsters
8. Infertility Rate Among Indian Couples
9. Awareness about Investment & Foreign Collaboration of Indian players

RECOMMENDATION & SUGGESTIONS
The most important economic issues in contemporary ART markets are:
1) Access to treatment
2) Treatment success, as measured through birth rates and multiple birth rates.
These issues of access and quality are also the central concerns for Indian health care markets in
general.
• Across the medical sector of the economy and in IVF markets in particular,
it has been suggested that altering the competitive structure of markets or the extent of
insurance coverage can improve both access to care and quality.
• In the market for infertility treatment, mandatory insurance coverage is predicted to bring
new patients into the market and reduce the incentive to transfer a dangerously high number
of embryos during treatment, thereby increasing the quality of care.
• While price reducing competition is likely to improve access to IVF, there exist concerns that
competing clinics will attempt to win new patients by inflating birthrates using treatments that
also raise the risk of multiple births.

RECOMMENDATION & SUGGESTIONS
• However, concerns about quality-reducing competition may be incorrect, and in fact additional
competition can decrease multiple birth rates by reducing patients’ incentive to seek aggressive
treatment for their fertility problems. With the present paper we evaluate the impacts of both
mandated insurance coverage and an increase in competition on ART access and treatment
success rates.

• We expect the use of IVF to continue to grow, as treatment expenses fall with competition and
technological progress, and more women account for the possibility of ART while making related
life cycle choices regarding education, career, and marriage.

• Indeed, the changing economic environment of the late 21st century is likely to have shifted
substantially the demand for infertility treatment services.
• As women’s labor force participation rates and real wages have increased, couples have deferred
the decision to have children

RECENT UPDATES/ REASERCH IN WORLD IVF MARKET
• Cooper To Lead In Vitro Fertilization Market Following $189 Million Origio
Acquisition ,Deal will boost Cooper’s share of the $220 million global IVF
market from 7% to 39%.
• Discovery of a Molecule That Initiates Maturation of Mammalian
Eggs Can Lead to More IVF Pregnancies
researchers at the University of Gothenburg have identified a
molecule called Cdk1 that has an important function for mammalian
egg maturation. In the future this could lead to an increased rate of
successful IVF.
This is the first functional evidence that Cdk1 is a key molecule in
mammalian egg maturation. If the results can be translated into
clinical settings, it could possibly improve the chances of successful
IVF treatment for women who today are not becoming pregnant
because their eggs do not mature" says Kui Liu, professor at the
Department of Chemistry and Molecular Biology, the University of
Gothenburg, Sweden.

RESEARCH IN WORLD IVF MARKET
• A new technique successfully used in mice to identify embryos likely to result in a successful
pregnancy could be used in humans, according to University scientists.
The Cardiff scientists worked with a team in Oxford University to analyse the internal contents
of the human egg or cytoplasm to observe distinct rhythmic patterns.
"Current IVF treatment involves fertilising eggs in the laboratory and then choosing those embryos
considered to be the healthiest for implantation into the mother's womb, using selection
criteria such as the number and appearance of cells produced during the division process,"
according to Professor Karl Swann, School of Medicine, who led the research.
• New Method for Picking the 'Right' Egg in IVF:
• groundbreaking study,Yale School of Medicine researchers and colleagues at the
University of Oxford have identified the chromosomal make-up of a human egg.
This discovery may soon allow them to avoid using abnormal -- or aneuploid --
eggs during infertility treatments, and instead to pick eggs that are healthy
enough for a successful in vitro fertilization (IVF) cycle.
• "This finding opens up the possibility of a safe, effective, and inexpensive way of
identifying healthy eggs, potentially lowering the risks of miscarriage and Down
syndrome," said Wells. "By conducting these tests before eggs are
fertilized, ethical concerns about analysis of human embryos are avoided."

FUTURE OF INFERTILITY TRATMENT
The development of techniques to prolong the window of fertility for women has the ability
to meet the needs of future populations and their delay in childbearing.
With current techniques of cryopreservation of embryos, oocytes, or ovarian
tissue, prolongation of fertility with varying success is feasible.
In the future, rejuvenation of aging oocytes will offer the opportunity for the aging women
to achieve pregnancy with their own genetic offspring.
Production of germ cells from embryonic stem cells is another alternative for patient with
poor or depleted germ cells.
Better understanding of the cause of infertility can be achieved with new techniques to
evaluate the oocytes, spermatozoa, and embryos on molecular and genetic levels.
With improved understanding of the etiology of infertility, treatment will be more effective.
With the advance of new drugs and surgical equipment, treatment of infertility will become
more convenient and effective.

UPCOMING CONFERENCES - INDIA

Indian Society for the Study of Reproduction and Fertility (ISSRF)
The 23rd Annual Meeting of the ISSRF along with an International Conference on Repromics-
Omics in Reproduction and Development will be held at the Rajiv Gandhi Centre for
Biotechnology, Thiruvananthapuram during February 7-9, 2013.
The relevant information will be up-loaded from time to time and will be circulated to all
members of the Society.
The contact person is:
Dr. Pradeep Kumar G
Scientist F
Rajiv Gandhi Centre for Biotechnology
Thycaud Post, Poojappura
Thiruvananthapuram - 695014, Kerala, India
Tel.: +91-471-2529459
E-mail: kumarp@rgcb.res.in


8th Annual National Conference of Indian Fertility Society on "INFERTILITY & ASSISTED
REPRODUCTIVE TECHNOLOGIES" 8th & 9th December, 2012 ( 13 Dec, 2012 )


Conference Name : Amasicon2006:

Date & Venue : March 31st April 1st & 2nd Kolkata, Hotel Hyatt Regency-Venue,

Contact Address : ILS MultispecialityClinic-Surgery, Jeewansatya, DD-6, Sector 1,

Salt Lake City, Kolkota, West Bengal Pin:700064

Office & Mobile Phone : Office: +91-33-23593700, Mobile: +91-9830400300, Telefax: +91-33-23214912

Email & Web : Email: secreteriat@amasicon2006.com Web: www.amasicon2006.com

UPCOMING INTERNATIONAL CONFERENCES - INTERNATIONAL

2012-06-13
International Society for Stem Cell Research 10th Annual Meeting
Dates: June 13-16. 2012
Location: Pacifico Yokohama, Yokohama, JAPAN
For more information: http://www.isscr.org 2012-06-16
2012 AMA Annual Assembly Meeting
Dates: June 16-20, 2012
Location: Chicago, IL, USA
For More Information:http://www.ama-assn.org
2012-06-20
Society of Obstetricians and Gynaecologists of Canada 68th Annual Clinical Meeting
Dates: June 20-24, 2012
Location: Ottawa, Ontario, CANADA
For more information: http://www.sogc.org 2012-06-23
ENDO 2012
Sponsor: The Endocrine Society
Dates: June 23-26, 2012
Location: Houston, Texas, USA
For more information: http://www.endo-society.org 2012-06-27
8th International Congress on Minimally Invasive Gynecology
Sponsors: American Association of Gynecologic Laparoscopists and the Romanian Society of Minimally Invasive Surgery in
Gynecology
Dates: June 27 - July 1, 2012
Location: Bucharest, ROMANIA
For more information: http://www.aagl.org 2012-07-01
ESHRE 2012
Description: 28th Annual Meeting of the European Society of Human Reproduction and Embryology
Dates: July 1-4, 2012
Location: Istanbul, TURKEY
For More Information:http://www.eshre.eu


International Academy of Sex Research 38th Annual Meeting
Dates: July 8-11, 2012
Location: Lisbon, PORTUGAL
For more information: http://www.iasr.org 2012-07-26
North American Council on Adoptable Children 38th Annual Conference
Dates: July 26–28, 2012
Location: Crystal City, Virginia, USA
For more information: https://www.nacac.org/conference/conference.html 2012-08-02
12th Asia-Oceania Federation of Sexology (AOFS) Meeting
Dates: August 2-5, 2012
Location: Matsue, JAPAN
For more information: http://www.12aocs.jp 2012-08-12
45th Annual Meeting of the Society for the Study of Reproduction
Theme: “Applied Reproductive Biology: Making It Relevant”
Dates: August 12–15, 2012
Location: The College of Agricultural Sciences, The Pennsylvania State University, State
College, Pennsylvania, USA
For more information: http://www.ssr.org 2012-08-22
11th Asian Congress of Urology
Sponsor: The Urological Association of Asia
Location: Pattaya, THAILAND
For more information: http://11thacu2012.org 2012-08-26


SMSNA/ISSM Joint Annual Meeting
Sponsor: Sexual Medicine Society of North America
Location: Sheraton Chicago Hotel & Towers, Chicago, IL, USA
For More Information: http://www.smsna.org
2012-09-05
21st SLS Annual Meeting and Endo Expo 2012
Sponsor: Society of Laparoendoscopic Surgeons
Dates: September 5-8, 2012
Location: Westin Copley Place, Boston, MA, USA
For More Information: www.sls.org
2012-09-06
CFAS 2012
Sponsor: Canadian Fertility and Andrology Society
Dates: September 6-9, 2012
Location: Ottawa Westin, Ottawa, Ontario, CANADA
For More Information: www.cfas.ca
2012-10-20
ASRM 2012
Description: 68th Annual Meeting of the ASRM
Dates: October 20-24, 2012
Place: San Diego Convention Center, San Diego, California, USA
For More Information: ASRM, Tel: 205-978-5000, Fax: 205-978-5018, Email: asrm@asrm.org


2012-12-06 (ESSM)

15th Congress of the European Society for Sexual Medicine (ESSM)
Dates: December 6-9, 2012
Location: Amsterdam, THE NETHERLANDS
For more information: http://www.essm.org 2013-03-07

The Best of ESHRE & ASRM
Dates: March 7-9, 2013
Location: Atlantis, Paradise Island, BAHAMAS
For more information: http://www.asrm.org/Atlantis2013/ 2013-04-17

2013 Pacific Coast Reproductive Society Annual Meeting
Dates: April 17-21, 2013
Location: Renaissance Esmeralda, Indian Wells, CA, USA
For More Information: http://www.pcrsonline.org

2013-05-04

2013 ACOG Annual Clinical Meeting
Dates: May 4-8, 2013
Location: New Orleans, LA, USA
For More Information: http://www.acog.org/

2013-06-15

Dates: June 15-19, 2013
For More Information: http://www.ama-assn.org

2013-10-12

Joint ASRM/IFFS Meeting
Description: 69th Annual Meeting of the ASRM held conjointly with the Meeting of the International Federation of Fertility Societies
Place: Boston Convention and Exhibition Center, Boston, MA, USA
For More Information: ASRM, Tel: 205-978-5000, Fax: 205-978-5018, Email: asrm@asrm.org: Website: http://www.asrm.org/IFFS-ASRM2013/

2014-04-23

2014 Pacific Coast Reproductive Society Annual Meeting
Dates: April 23-27, 2014
Location: Renaissance Esmeralda, Indian Wells, CA, USA
For More Information: http://www.pcrsonline.org


2014-06-07

Dates: June 7-11, 2014

2014-10-18

ASRM 2014
Description: 70th Annual Meeting of the ASRM
Place: Hawaii Convention Center, Honolulu, HI, USA

2015-06-06
Dates: June 6-10, 2015

2015-10-17

ASRM 2015
Description: 71st Annual Meeting of the ASRM
Place: Baltimore Convention Center, Baltimore, MD, USA
2016-06-11

Dates: June 11-15, 2016
For More Information:http://www.ama-assn.org

Ivf market trends and an overview

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Similar a Ivf market trends and an overview

Similar a Ivf market trends and an overview (20)

Más de Ishan Shukla

Más de Ishan Shukla (6)

Último

Último (20)

Ivf market trends and an overview